跳到正文
PR Newswire 健康·· 11 天前AI 评分34

ImmunoGenesis 公布两篇论文:STING 激动剂 IMGS-203 联合 PD-L1/PD-L2 双特异性抗体可克服肿瘤免疫耐药

ImmunoGenesis Announces Two Publications Highlighting the Potential of IMGS-203, a Novel Stimulator of Interferon Genes (STING) Agonist, to Overcome Tumor Immune Resistance and Enhance Antitumor Efficacy in Combination with a Cytotoxic Dual-specific PD-L1/PD-L2 Antibody

AI 导读

ImmunoGenesis 公布两篇论文,非临床证据显示其新型 STING 激动剂 IMGS-203 经局部给药可重塑肿瘤微环境、减少免疫抑制性髓系细胞并增强 T 细胞活化,与公司细胞毒性 PD-L1/PD-L2 双特异性抗体联用可提升抗肿瘤活性。数据支持 IMGS-203 首先开发用于复发胶质母细胞瘤(GBM),公司正完成 IND 申报研究以推进临床开发。

正文 · 原文

, /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced two publications providing new nonclinical evidence and scientific insights into the ability of its novel stimulator of interferon genes (STING) agonist, IMGS-203, to remodel the tumor microenvironment and enhance antitumor activity in combination with the Company's novel cytotoxic dual-specific PD-L1/PD-L2 antibody.

IMGS-203 is a novel STING agonist being developed by ImmunoGenesis as a cancer immunotherapy designed to stimulate antitumor immune responses. The Company plans to advance IMGS-203 into clinical development initially for recurrent glioblastoma (GBM), an aggressive brain cancer with limited therapeutic options and significant unmet medical need.

Dr. Federica Pericle, Chief Scientific Officer, ImmunoGenesis, commented: "These findings reinforce the scientific rationale for developing IMGS-203 in GBM, where local STING activation has the potential to overcome the immunosuppressive tumor microenvironment. We are completing IND-enabling studies to advance IMGS-203 into clinical development while exploring its potential in combination with our cytotoxic dual-specific PD-L1/PD-L2 antibody."

The data from these publications are directly relevant to GBM, a highly immunosuppressive, myeloid-rich tumor in which monotherapy with conventional immune checkpoint inhibitors have shown limited efficacy. Nonclinical studies demonstrate that local administration of IMGS-203 remodels the tumor microenvironment (TME), reduces immunosuppressive myeloid cell populations, enhances T-cell activation, and improves survival in tumor models. STING activation also induces PD-L1 and PD-L2 expression, creating an opportunity to enhance antitumor activity through combination with ImmunoGenesis' cytotoxic dual-specific PD-L1/PD-L2 antibody.

 "Together, these publications reinforce our commitment to translating STING biology into innovative cancer therapies," said James Barlow, President and Chief Executive Officer, ImmunoGenesis. "We are focused on advancing IMGS-203 into clinical development for patients with GBM, a devastating disease with limited treatment options and significant unmet clinical need."

Publication Details:
Salameh, et al., (2026), Tumor Microenvironment Remodeling by STING Agonism Sensitizes Endothelial Cells to Cytotoxic anti-PD-L1/L2 Antibody in Journal of Experimental and Clinical Cancer Research highlights promising results showing activation of the STING pathway can overcome immune exclusion by promoting Tumor Microenvironment (TME) remodeling and immune cell recruitment. 

Boda et al., (2026) "STING-Mediated Tumor Microenvironment Remodeling: Turning Adaptive Resistance into Therapeutic Vulnerability." Frontiers in Immunology reviews data showing how STING activation can reconfigure the TME to yield potent anti-tumor effects.

About ImmunoGenesis
ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2. IMGS-001 is currently in a phase 1a/b clinical trial for the treatment of immune-excluded tumors, which account for more than half of all cancers. In addition to its lead program, the company is developing a multi-mechanism strategy aimed at addressing the pathology of immune-excluded tumors by overcoming immune exclusion to enable a robust immune response in the tumor microenvironment. For more information, visit immunogenesis.com.

Contacts:

James Barlow, President and CEO 
James.Barlow@immunogenesis.com

SOURCE Immunogenesis Inc.

来源:PR Newswire 健康 · prnewswire.com